This agenda is from the 2018 show. The 2019 agenda is to be announced closer to the show.
Wednesday 6th June
Thursday 7th June
11.00 - 11.30
Dr Matt Brown
As the oncological landscape shifts in response to the improved diagnosis and treatment of malignancy, so the causes and types of pain encountered in cancer patients change. Pain is the most feared symptom of patients with advanced cancer and remains a major area of unmet clinical need. Poorly controlled pain results in markedly reduced quality of life and commonly impacts on treatment compliance and overall clinical outcomes. This seminar will provide an overview of current hot-topics in the field of cancer pain including; chemotherapy induced peripheral neuropathy, pain in cancer survivors and the challenges posed by the ‘opioid crisis’.
11.45 - 12.15
Will talk about my Head & Neck cancer journey, vision of the Swallows Support Group and how within 6 years I end up in the palace receiving an MBE for the charity.
12.30 - 13.00
Professor Patricia Price
We will discuss the roles of the charity in supporting patients and professionals; our daily newsfeed, patient and professionals’ resources, technical radiotherapy forum, Facebook page and Twitter following.
13.15 - 13.45
Dr Shreerang Bhide
Following chemo-radiotherapy (CCRT) for human papilloma virus positive (HPV+) locally advanced head and neck cancer, patients frequently undergo unnecessary neck dissection (ND) and/or repeated biopsies for abnormal PET-CT, which causes significant morbidity. We assessed the role of circulating HPV DNA in identifying “true” residual disease using a novel next generation sequencing assay – HPV-detect.
14.00 - 14.30
Philip Beer MRCP, FRCPath, PhD
Parallel advances in sequencing technology and synthetic chemistry have delivered a near-complete lexicon of genomic cancer drivers alongside the ability to target with therapeutic intent a diverse range of oncogenic molecules. Despite this progress, however, the impact of molecularly-targeted therapy has to date been relatively modest. Important barriers to the full realisation of the power of cancer genomics include the availability and reimbursement of genomic testing, access to suitably comprehensive testing, identification of biologically significant (‘driver’) mutations, and the reporting of complex genomic data in a clinically meaningful way. Perhaps most significant of all is a pressing need to re-evaluate approaches to clinical trial design and patient stratification in light of recent advances in our understanding of how cancers evolve to evade targeted and immune-based therapies.
14.45 - 15.15
Mr Naga Venkatesh Jayanthi MD, FRCS
Consultant Laparoscopic & Robotic Surgeon Cancer Lead, Essex Upper GI, Regional Centre for Gastro-Oesophageal Surgery, Broomfield Hospital, Chelmsford. UK Honorary Senior Lecturer, Queen Mary University London